Sherif Abdou: So thank you, Jenny. Nice to meet you. Tell David and say hi. So the delegated lives are now, like I said, is about 20%. We are targeting to reach about, I want to say, 30%, 35%. Pretty much all the new contracts that we signed, like with SCAN and others, are fully delegated. So a lot of that growth and Humana that we signed in Nevada, that’s fully delegated. So all this will come in with fully delegated and we’re hoping to grow those. We are in discussion with United, Aetna and Centene to convert, and that would be the other 60% of lives that we have. That then we will head to 90% mark. So that is the trajectory that we have.
Jenny Shen: Okay. That sounds great. And then just on the ACO REACH side of the business, I think you’ve mentioned before that they generally start out with lower margins than MA, but they ramp up to be equal or even better. Just any thoughts on that opportunity and the timeline to ramping?
Bill Bettermann: Jenny, this is Bill. So actually, some of the recent data that we’ve seen is that even overall, the new lives coming in on ACO REACH are actually quite profitable. But as we see over time, they continue to grow just like our Medicare Advantage lives. So we actually see a very nice pop with our new ACO REACH lives as well as those persistent ACO REACH lives that we will see in the coming years.
Jenny Shen: Okay. Great. And just the last one for me. Any thoughts on the current utilization trends? And any details in terms of like inpatient versus outpatient utilization, and maybe some thoughts on GLP-1? Thanks.
Amir Bacchus: Hi, Jenny. Dr. Bacchus here. So as far as we said, I mean we’ve actually been able to bend that cost curve down. We were down by 2% over this last year with the expenditures of people who we’re very, very concerned with. So jumping right to the GLP-1 question. Yes, we do have patients that are utilizing GLP-1s, but we’re also seeing clinical improvements in regards to cardiovascular disease and the other things that we use GLP-1s for, not necessarily just for blood sugar alone. It is nice to see that for our population being senior populations, it’s not necessarily something that you see like in commercial populations where a lot of people are using GLP-1 for potential weight loss and things like that. So we are a little bit, I’ll say covered with our senior populations that we manage.
From an inpatient standpoint and things like that, we continue to do and work with our plans. We are able to do concurrent review, especially on not only those delegated lives but also we do have some UM opportunities where we’re not fully delegated. So we’ll continue to do that as well and work with our plans to improve inpatient utilization, whether it’s direct hospitalization or even post-acute. So those are all things that we look at as well as being able to risk stratify our population very, very well to understand who are those populations at risk that are very high-cost, high-risk, rising risk populations so that our care management teams are working directly with not only our CMOs in our markets, but directly with our providers and patients to maximize their care and access.
So these are all things that we do collectively to drive down that medical expense, and we have some real good actions going forward into ’24.
Sherif Abdou: Ryan, by the way, the question about the age, the average age of the persistent life is 73 years old.
Operator: This concludes our question-and-answer session. I would like to turn the conference over to Dr. Sherif Abdou for any closing remarks.
